FDA拒绝批准中国开发的某抗癌药物
FDA Rejects Promising Cancer Drug Developed in China
FDA未批准靶向PD-1和VEGF的bispecific抗体Ivonescimab用于治疗EGFR突变的NSCLC,尽管该药在亚洲患者中显示出OS改善,未来可能在其他适应症获批。
FDA未批准该药,但其在亚洲患者中显示出OS改善,未来仍有其他适应症的批准机会。
— Ivonescimab failed to meet overall survival endpoint in pretreated EGFR-mutant lung cancer trial
November 16, 2026 • 2 min read
The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon have other chances at approval.
The company said the FDA issued a complete response letter explaining that it could not approve ivonescimab, which targets PD-1 and VEGF, because a late-stage trial in previously treated EGFR-mutant locally advanced or metastatic NSCLC failed to demonstrate a significant overall survival (OS) benefit.
In the phase III HARMONi trial, the combination of ivonescimab and platinum-containing chemotherapy did prolong progression-free survival (PFS), the other co-primary endpoint. Among patients treated with standard chemotherapy after progressing on third-generation EGFR tyrosine kinase inhibitors, median PFS was 6.8 months with ivonescimab versus 4.4 months with placebo (HR 0.52, 95% CI 0.41-0.66, P<0.0001), though a greater PFS benefit was demonstrated in Asian patients compared with a North American/European subset.
A numerical difference in median OS favoring ivonescimab (16.8 vs 14 months with placebo) failed to meet statistical significance (HR 0.79, 95% CI 0.62-1.01, P=0.057).
"The FDA indicated that the PFS benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval," Summit said in its press release.
The drug is approved for several NSCLC indications in China.
Results from the HARMONi-6 trial, presented at this year's American Society of Clinical Oncology annual meeting, showed that ivonescimab combined with chemotherapy significantly improved OS in an all-Asian population with advanced squamous NSCLC compared with tislelizumab (Tevimbra) plus chemotherapy.
Meanwhile, in updated results from the HARMONi-2 trial presented this year at the World Conference on Lung Cancer, ivonescimab significantly improved OS compared with pembrolizumab (Keytruda) in Chinese patients with PD-L1-positive advanced NSCLC.
The HARMONi-3 trial is evaluating ivonescimab versus pembrolizumab as a frontline NSCLC treatment in a global population, including U.S. patients.
The HARMONi-7 trial is also assessing ivonescimab as a first-line treatment for metastatic NSCLC in a PD-L1-high population.
Summit purchased the U.S. rights to the drug from Akeso Biopharma, which developed the drug and markets it in China.
Ivonescimab is also being evaluated in other solid tumors, including colorectal cancer, urothelial carcinoma, and renal cell carcinoma.
来源:MedPage Today · medpagetoday.com